A Canadian, Phase IV, Multicenter, Comparative, Open-label Study Evaluating 2 Approaches of Blood Glucose Monitoring and Insulin Titration (Patient-managed vs Health Care Professional) in T2DM Patients While Receiving the Addition of 1 Injection of Insulin Glulisine at Breakfast Following Optimization of Insulin Glargine.

Trial Profile

A Canadian, Phase IV, Multicenter, Comparative, Open-label Study Evaluating 2 Approaches of Blood Glucose Monitoring and Insulin Titration (Patient-managed vs Health Care Professional) in T2DM Patients While Receiving the Addition of 1 Injection of Insulin Glulisine at Breakfast Following Optimization of Insulin Glargine.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2013

At a glance

  • Drugs Insulin glargine; Insulin glulisine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms START
  • Sponsors Sanofi
  • Most Recent Events

    • 20 Mar 2012 Actual patient number is 493 according to ClinicalTrials.gov.
    • 20 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 May 2011 Planned End Date changed from 1 Jul 2011 to 1 Jan 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top